Skip to main content

Table 3 Percent antibiotic susceptibility of Acinetobacter spp. and P. aeruginosa during 2015/2016 compared to corresponding susceptibility results in 2011/2013a

From: A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015–2016

Antibiotic Acinetobacter spp P. aeruginosa
2011/2013 N (% S) 2015/2016 N (% S) OR (95% CI) P 2011/2013 N (% S) 2015/2016 N (% S) OR (95% CI) P
Amikacin 3329 (16%) 3675 (19%) 1.23 (1.11–1.36) 0.0001 7675 (89%) 9005 (85%) 0.70 (0.62–0.79) 0.0001
Aztreonam NA NA NA NA 7483 (76%) 7457 (79%) 1.19 (1.06–1.33) 0.002
Cefepime 3409 (13%) 3675 (13%) 1.00 (0.89–1.12) 1 7897 (83%) 9005 (81%) 0.87 (0.79–0.97) 0.01
Ceftazidime 3343 (12%) 3675 (13%) 1.10 (0.973–1.23) 0.14 7897 (82%) 9005 (80%) 0.88 (0.79–0.97) 0.01
Ciprofloxacin 3379 (12%) 3675 (11%) 0.91 (0.80–1.02) 0.12 7897 (77%) 9005 (73%) 0.81 (0.74–0.89) 0.0001
Gentamicin 3384 (19%) 3675 (14%) 0.70 (0.62–0.78) 0.0001 7722 (83%) 9005 (81%) 0.87 (0.79–0.97) 0.01
Imipenem 3409 (18%) 3675 (12%) 0.62 (0.56–0.70) 0.0001 7897 (73%) 9005 (70%) 0.86 (0.79–0.94) 0.001
Piperacillin/tazobactam 3343 (13%) 3675 (11%) 0.83 (0.73–0.93) 0.12 7897 (80%) 9005 (78%) 0.89 (0.80–0.98) 0.02
  1. KEY = CI confidence interval, N Number of isolates tested in each bacteria/antibiotic combination, NA not available, OR Odds Ratio, S Susceptibility, % percent
  2. P < 0.05 is considered statistically significant
  3. aThe 2011/2013 data are taken from: Chamoun K, Farah M, Araj G, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data. Int J Infect Dis. 2016;46:64–70